SCHEMBL17397635

SCHEMBL17397635

CCc1cc(C(=O)OC)ccc1C1CCN(C(=O)O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.48
ALDH1A1 P00352 8/20 0.41
KDM4E B2RXH2 6/20 0.41
LMNA P02545 1/20 0.41
EPHX2 P34913 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
PPM1D O15297 1/20 0.39
CCR2 P41597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397765 0.88 RBP4 (0.47) RBP4ALDH1A1KDM4ELMNAEPHX2
SCHEMBL19155007 0.87 CHRNB2 (0.45) RBP4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL19107668 0.85 PDE4A (0.47) RBP4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL3652239 0.84 RBP4 (0.52) RBP4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL28128251 0.81 RBP4 (0.43) RBP4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL17397553 0.81 CHRNB2 (0.46) RBP4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL17395670 0.80 MGLL (0.40) KMT2AMEN1MAPT
SCHEMBL17395599 0.79 SLC9A1 (0.38) RBP4KMT2AMEN1MAPTRAB9A
SCHEMBL17595671 0.78 RBP4 (0.51) RBP4ALDH1A1KDM4ELMNAEPHX2
SCHEMBL17397790 0.78 NPC1 (0.39) ALDH1A1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550102-B2 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators NOVARTIS AG (CH) 2020-02-04 US disclosed
US-10316020-B2 Indane derivatives and the use thereof as soluble guanylate cyclase activators NOVARTIS AG (CH) 2019-06-11 US disclosed
US-20190119254-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2019-04-25 US disclosed
EP-3164395-B1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS AG (CH) 2019-03-27 EP disclosed
US-10208018-B2 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators NOVARTIS AG (CH) 2019-02-19 US disclosed
US-20190002438-A1 INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2019-01-03 US disclosed
EP-3390386-A1 INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS AG (CH) 2018-10-24 EP disclosed
US-20170197940-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS AG (CH) 2017-07-13 US disclosed
WO-2017103888-A1 INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS AG (CH) 2017-06-22 WO disclosed
EP-3164395-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS Novartis AG (CH) 2017-05-10 EP disclosed
WO-2016001875-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS NOVARTIS AG (CH) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197940-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, PDE3A RBP4 4826/4885ALDH1A1 1087/4885KDM4E 2747/4885
US-10316020-B2 Indane derivatives and the use thereof as soluble guanylate cyclase activators GUCY1A2, GUCY1A1, GUCY1B1 RBP4 4781/4885ALDH1A1 776/4885KDM4E 3082/4885
US-10550102-B2 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators GUCY1A2, GUCY1A1, PDE3A RBP4 4826/4885ALDH1A1 1087/4885KDM4E 2747/4885
US-20190002438-A1 INDANE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, GUCY1B1 RBP4 4781/4885ALDH1A1 776/4885KDM4E 3082/4885
US-10208018-B2 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators GUCY1A2, GUCY1A1, PDE3A RBP4 4826/4885ALDH1A1 1087/4885KDM4E 2747/4885
US-20190119254-A1 INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, PDE3A RBP4 4826/4885ALDH1A1 1087/4885KDM4E 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.